Download damae medical

DAMAE MEDICAL
One line pitch:
Skinsight® is a medical device providing dermatologists a way to visualise skin tissues without
being invasive, & more accurate in cancer detection.
Market Analysis:
The incidence of both non-melanoma and melanoma skin cancers has been multiplied by more
than three between 1980 and 2005. Currently, between 2 and 3 million non-melanoma skin
cancers and 132,000 melanoma skin cancers occur globally each year.One in every three cancers
diagnosed is a skin cancer and one in every five Americans and one in three Australians will
develop skin cancer in their lifetime.Diagnosis of skin cancers mainly depends on a clinical
examination of suspicious lesions followed by a biopsy and histopathological analysis using an
optical microscope. This process is long, inneficient and in need of modernisation.
Business Proposition:
Our device provides a way to see under your skin at a cellular level.Our innovation is a technology
that meets all of the dermatological criteria (performed by one device in a single setting).
SkinSight® combines all advantages in terms of resolution, penetration depth, imaging orientation.
SkinSight® provides physicians with significant clinical advantages by allowing accurate
assessment for all types of skin cancers without limitations, and for all invasiveness stages
evaluation, with high resolution. SkinSight® thus appears as a key tool for the dermatologist to
correctly diagnose and optimize the therapeutic management of their patients.
Competitive Advantage:
Several optical imaging techniques have been developed by European and US-based companies,
to allow for in situ cutaneous tumors characterization in a non-invasive way: confocal microscopy
(CM), optical coherence tomography (OCT), high definition OCT (HD-OCT). However, those
systems are still limited in terms of imagery performance (such as resolution or imaging depth)
resulting in limited clinical performances. Our device shows a better resolution, a higher
penetration rate and can identify more pathologies while providing vertical images, very similar ot
current histologies.
Investment Attractiveness:
DM represents a real opportunity for investements for several reasons. First, the Incidence of skin
cancer is sadly increasing evert year, resulting in a growing market of the imaging device in
dermatology. Public authorities are also mobilised and are therefore facilitating the market access
and increasing awarness around early stage detection. Secondly, beyond the dermatology market
our technology can also reach huge markets such as research in cosmetology or
pharmaceuticals. Finally, DAMAE Medical could be traded to an industrial company as it is the
case for many med tech strat ups from 2018, to giants such as GE, Phillips etc.
COMPANY PROFILE
• Website:
www.damaemedical.fr
• Activity: MedTech
• Contact:
BARUT Anais
[email protected]
• Location:
96 bis Boulevard Raspail
75006
France
• Founded in: 17/09/2014
• Employees: 12
• Management:
Barut Anais
CEO
Siret David
CTO
Dubois Arnaud
CSO
• Financial information (€):
- Company stage:
validation
- Capital raised to date:
IP Situation:
- Monthly burn rate:
SkinSight® uses a patented technology (ownership: CNRS, Université Paris Sud, Institut
D'Optique Graduate School) and has reached a mature level of development. The device has
been acknowledged by prestigious KOLs in skin cancer management and is now entering its
clinical trial phase while obtaining regulatory approvals.
- Capital seeking and date:
• Investors:
• Referred by:
CNRS, Université Paris Sud,
Institut d'Optique Graduate
School